Cognition Therapeutics, Inc. Shareholders' Equity
Cognition Therapeutics, Inc. (CGTX) had Shareholders' Equity of $33.02 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent $33.02M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $29.91M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $34.27M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $36.53M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $33.02M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $29.91M 10-Q · filed 2026-08-07 |
| 2025-12-31 | $34.27M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $36.53M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $7.03M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $12.27M 10-Q · filed 2026-08-07 |
| 2024-12-31 | $18.75M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $14.48M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $23.01M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $28.86M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $24.47M 10-K · filed 2026-03-26 |
| 2023-09-30 | $28.93M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $34.39M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $35.78M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $40.25M 10-K · filed 2025-03-20 |
| 2022-09-30 | $39.32M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $43.90M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $48.74M 10-Q · filed 2023-11-02 |
| 2021-12-31 | $51.27M 10-K · filed 2024-03-26 |
| 2021-09-30 | -$86.72M 10-Q · filed 2022-11-14 |
| 2021-06-30 | -$83.68M 10-Q · filed 2022-11-14 |
| 2021-03-31 | -$67.85M 10-Q · filed 2022-11-14 |
| 2020-12-31 | -$68.18M 10-K · filed 2023-03-23 |
| 2020-09-30 | -$66.49M 10-Q · filed 2021-11-17 |
| 2020-06-30 | -$64.51M 10-Q · filed 2021-11-17 |
| 2020-03-31 | -$61.97M 10-Q · filed 2021-11-17 |
| 2019-12-31 | -$58.42M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |